The invention relatests compound of formula (I):
1
wherein:
n is 1, 2 or 3,
A represents a group
2
X represents N or NR
1
,
R
2
represents an alkoxy, cycloalkyloxy or cycloalkylalkyloxy group.
and medicinal products containing the same which are useful in treading or in preventing melatoninergic disorder.
The invention relatests compound of formula (I):
wherein: n is 1, 2 or 3,
A represents a group
or a group
X represents N or NR
1
,
R
2
represents an alkoxy, cycloalkyloxy or cycloalkylalkyloxy group. and medicinal products containing the same which are useful in treading or in preventing melatoninergic disorder.
Successors of agomelatine: A series of isoquinoline and tetrahydroisoquinoline derivatives were shown to have good melatonergic affinity and no 5-HT2C affinity. Compounds 38 and 43 demonstrated the most interesting binding affinities, whereas tetrahydroisoquinoline 23 showed 45-fold MT2 selectivity over the MT1 receptor subtype.